07:07 AM EST, 11/13/2026 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Kuraci's Donrafylix, a biosimilar of Novo Nordisk's (NOVO-B.CO) NovoRapid, for diabetes mellitus. The biosimilar insulin aspart, available as a 100 units/milliliter solution for injection, is intended for adults, adolescents and children aged one year and above with the condition, according to a Friday notice.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.